ReviewWorld journal of gastroenterology2015
Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Drug Use and Social Connectivity Related to Hepatitis C Infection Among Rural People Who Use Drugs.Journal of viral hepatitis · 2026Article
- Serological and Molecular Prevalence of HCMV, HCV, HBV andCurrent HIV research · 2026Article
- Review
- Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy.Frontiers in cellular and infection microbiology · 2025Article
- Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study.PLOS global public health · 2025Article
- Development of a Lateral Flow Assay for the Detection of the Hepatitis C Virus Core Antigen.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Chinese mainland and a phylogenetic analysis.Infectious diseases of poverty · 2023Article
- HCV Genotype Distribution Among People Who Inject Drug in Turkey: Findings from Multicenter and Cross-Sectional Study.Substance abuse : research and treatment · 2023Article
- Article
- Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens.Open forum infectious diseases · 2021Article
- Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs.Journal of clinical medicine · 2021Article
- Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China.Journal of clinical and translational hepatology · 2021Review
- Review
- Sociodemographic Factors Associated With HIV/HCV High-Risk Behaviors Among People Who Use Drugs on Methadone Maintenance Treatment: A 10-Year Observational Study.Frontiers in psychiatry · 2021Article
- Distribution of HCV Genotypes Among People Who Inject Drugs in Tunisia: New Evidence for Scaling Up Prevention and Treatment Toward National Elimination Goal.Frontiers in microbiology · 2021Article
- Hepatitis C incidence and prevalence among Puerto Rican people who use drugs in New York City.Global public health · 2020Article
- Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review.Infectious diseases and therapy · 2019Review
- Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.Infection · 2018Review
- Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy.The Milbank quarterly · 2018Article
- Low prevalence of HCV infection with predominance of genotype 4 among HIV patients living in Libreville, Gabon.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Hepatitis C virus (HCV) genotypes' monitoring allows real-time insight into the dynamic changes that occur in the global epidemiological picture of HCV infection. Intravenous drug use is currently the primary driver for HCV transmission in developed and developing countries. The distribution of HCV genotypes/subtypes differs significantly between people who inject drugs (PWID) and the general population. HCV genotypes that previously exhibited a limited geographical distribution (3a, 4) are becoming more prevalent in this high-risk group. Immigration from HCV-endemic countries and the evolving networks of HCV transmission in PWID influence HCV genotypes distribution in Europe. Social vulnerabilities (e.g., unemployment, homelessness, and limited access to social and healthcare insurances systems) are important triggers for illicit drug use, which increases the associated risks of HCV infection and the frequent emergence of less prevalent genotypes. Genotype/subtype determination bears important clinical consequences in the progression of liver disease, susceptibility to antiviral therapies and the emergence of resistance-associated variants. An estimated half of the chronically HCV-infected PWID are unaware of their infection, and only one in ten of those diagnosed enter treatment. Nevertheless, PWID exhibit high response rates to new antiviral regimens, and the level of HCV reinfection is unexpectedly low. The focus of the healthcare system must be on the early detection and treatment of infection, to avoid late presentations that are associated with high levels of viremia and liver fibrosis, which may diminish the therapeutic success rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.